Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585007 | 1.00 | MC4R (0.35) | MC4RIDO1KDM4EALDH1A1TDP1 | |
| SCHEMBL8902161 | 0.83 | MC4R (0.34) | MC4RIDO1KDM4EALDH1A1TDP1 | |
| SCHEMBL3588737 | 0.80 | IDO1 (0.35) | MC4RIDO1 | |
| SCHEMBL3588742 | 0.79 | MC4R (0.38) | MC4RIDO1KDM4EALDH1A1 | |
| SCHEMBL26178209 | 0.79 | MC4R (0.38) | MC4RIDO1KDM4EALDH1A1 | |
| SCHEMBL9927907 | 0.79 | IDO1 (0.41) | MC4RIDO1KDM4EALDH1A1 | |
| SCHEMBL26706592 | 0.77 | NCF1 (0.33) | KDM4EALDH1A1TDP1 | |
| SCHEMBL3590243 | 0.76 | MC4R (0.33) | MC4RKDM4E | |
| SCHEMBL13635723 | 0.76 | MC4R (0.36) | MC4RIDO1 | |
| SCHEMBL3585361 | 0.76 | MC4R (0.41) | MC4RIDO1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | MC4R 3945/4885IDO1 459/4885KDM4E 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.